BIOXCEL THERAPEUTICS

0,6631

08-ноября-24 09:46:18

15 мин. задержка

Акции

-0,0070

-1,04%

Сегодняшний диапазон

0,6608 - 0,6800

ISIN

N/A

Источник

NASDAQ

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

08 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics to Present at ThinkEquity Conference

29 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

15 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

19 сен 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

05 сен 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

07 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Reports Second Quarter 2024 Financial Results

06 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024

30 июл 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

16 июл 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

25 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

28 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

21 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Reports First Quarter 2024 Financial Results

09 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

25 апр 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

24 апр 2024 09:30:24 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

22 апр 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia

10 апр 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces $25 Million Registered Direct Offering

25 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

15 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

12 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.